Journal for ImmunoTherapy of Cancer

Published by: Biomed Central Ltd  

People

  1. D'Angelo
    D'Angelo
  2. Tap
    Tap
  3. Antonescu
    Antonescu
  4. Richards
    Richards
  5. Avutu
    Avutu
  6. Barker
    Barker
  7. Bradic
    Bradic
  8. Budhu
    Budhu
  9. Chan
    Chan
  10. Chi
    Chi

Groups

  1. Department of Medicine (22)
  2. Hematologic Malignancies, Division of (22)
  3. Sarcoma Service (22)
  4. Solid Tumor Oncology Division (22)
  5. Department of Pathology and Laboratory Medicine (2)
  6. GSK Faculty (2)
  7. Tow Center for Developmental Oncology (TCDO) (2)
  8. Weinberg Fellows (2)
  9. Adult Leukemia (1)
  10. Center for Hematologic Malignancies (1)
Search Within
  1. "Sandra D'Angelo"
Formats
  1. Meeting Abstract (13)
  2. Journal Article (9)
Groups
  1. Department of Medicine (22)
  2. Hematologic Malignancies, Division of (22)
  3. Sarcoma Service (22)
  4. Solid Tumor Oncology Division (22)
  5. Department of Pathology and Laboratory Medicine (2)
  6. GSK Faculty (2)

More Groups

People
  1. Sandra D'Angelo (22)
  2. William Tap (5)
  3. Allison Richards (2)
  4. Cristina Antonescu (2)
  5. Ahmet Zehir (1)
  6. Anita Bowman (1)

More People

Years
  1. 2024 (1)
  2. 2022 (5)
  3. 2021 (2)
  4. 2020 (5)
  5. 2019 (5)
  6. 2018 (3)

More Years

Publishers
  1. Biomed Central Ltd (22)

Results (22)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A multicenter, randomized, non-comparative, phase II study of nivolumab ± ipilimumab for patients with metastatic sarcoma (Alliance A091401): Expansion cohorts and correlative analyses
    Journal Article

    Seligson, N. D.; Chen, J. L.; Goodrich, A. C.; Van Tine, B. A.; Campbell, J. D.; Richards, A. L.; Antonescu, C. R.; Liebner, D. A.; Milhem, M. M.; Streicher, H.; more...
    Journal for ImmunoTherapy of Cancer (2024)

    Fulltext@MSK | Save
  • First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from the JAVELIN Merkel 200 trial
    Meeting Abstract

    D'Angelo, S.; Lebbé, C.; Mortier, L.; Brohl, A.; Fazio, N.; Grob, J. J.; Prinzi, N.; Hanna, G.; Hassel, J.; Kiecker, F.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Post-hoc analysis from two phase I/II NY-ESO-1-TCR T-cell therapy clinical trials in patients with advanced sarcoma (SS or MRCLS) demonstrates response across a range of NY-ESO-1 expression
    Meeting Abstract

    Klohe, E.; Suchindran, S.; Kapoor, G.; D'Souza, J.; Corigleano, E.; Araujo, D.; D'Angelo, S.
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Biomarker correlates of letetresgene autoleucel (lete-cel; GSK3377794) response in patients with advanced myxoid/round cell liposarcoma (MRCLS)
    Meeting Abstract

    Kapoor, G.; Zajic, S.; Suchindran, S.; Kim, J.; Saxena, U.; Bhaskar, A.; Kaczynski, H.; Nathenson, M.; D'Souza, J.; Rich, B.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single center
    Journal Article

    Rosenbaum, E.; Antonescu, C. R.; Smith, S.; Bradic, M.; Kashani, D.; Richards, A. L.; Donoghue, M.; Kelly, C. M.; Nacev, B.; Chan, J. E.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival
    Journal Article

    Manitz, J.; D'Angelo, S. P.; Apolo, A. B.; Eggleton, S. P.; Bajars, M.; Bohnsack, O.; Gulley, J. L.
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Biomarker correlates of response in patients with advanced myxoid/round cell liposarcoma (MRCLS) treated with NY-ESO-1 TCR T Cells (letetresgene autoleucel)
    Meeting Abstract

    Kapoor, G.; Zajic, S.; Suchindran, S.; Kim, J.; Eleftheriadou, I.; Huff, A.; Nathenson, M.; Druta, M.; Van Tine, B.; Somaiah, N.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): Primary and biomarker analyses of a phase II study
    Journal Article

    D'Angelo, S. P.; Lebbé, C.; Mortier, L.; Brohl, A. S.; Fazio, N.; Grob, J. J.; Prinzi, N.; Hanna, G. J.; Hassel, J. C.; Kiecker, F.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Reveal: Phase 1 dose-escalation study of NKTR-262, a novel TLR7/8 agonist, plus bempegaldesleukin: Local innate immune activation and systemic adaptive immune expansion for treating solid tumors
    Meeting Abstract

    Diab, A.; Curti, B.; Bilen, M.; Brohl, A.; Domingo-Musibay, E.; Borazanci, E.; Fanton, C.; Haglund, C.; Vimal, M.; Muhsin, M.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Final analysis of the phase 1 trial of NY-ESO-1-specific T-cell receptor (TCR) T-cell therapy (letetresgene autoleucel; GSK3377794) in patients with advanced synovial sarcoma (SS)
    Meeting Abstract

    D'Angelo, S.; Demetri, G.; Van Tine, B.; Druta, M.; Glod, J.; Chow, W.; Pandya, N.; Hasan, A.; Chiou, V.; Tress, J.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save

    • Journal for ImmunoTherapy of Cancer – authorized name for:

    Name ISSN / ISBN Publisher
    Journal for ImmunoTherapy of Cancer 2051-1426 Biomed Central Ltd
    Journal for ImmunoTherapy of Cancer 2051-1426 Biomed Central Ltd
    Journal for ImmunoTherapy of Cancer 20511426 Biomed Central Ltd
    Journal for Immunotherapy of Cancer BMJ Publishing Group Ltd.
    Journal for ImmunoTherapy of Cancer 2051-1426 Biomed Central Ltd
    Journal for Immunotherapy of Cancer BMJ Publishing Group Ltd.
    Journal for ImmunoTherapy of Cancer 2051-1426 Biomed Central Ltd
    Journal for ImmunoTherapy of Cancer 20511426 Author(s) (or Their Emp Oyer(s)) 2025
    Journal for ImmunoTherapy of Cancer 20511426 Unknown
    Journal for ImmunoTherapy of Cancer 2051-1426 Biomed Central Ltd
    Journal for ImmunoTherapy of Cancer 2051-1426 Biomed Central Ltd
    Journal for ImmunoTherapy of Cancer 20511426 Author(s) (or Their Employer(s)) 2025
    Journal for ImmunoTherapy of Cancer 2051-1426 Biomed Central Ltd
    Journal for ImmunoTherapy of Cancer 20511426 The Author(s)
    Journal for ImmunoTherapy of Cancer 2051-1426 Biomed Central Ltd
    Journal for ImmunoTherapy of Cancer 2051-1426 Biomed Central Ltd
    Journal for ImmunoTherapy of Cancer 20511426 BMJ Group
    Journal for ImmunoTherapy of Cancer 2051-1426 Biomed Central Ltd
    Journal for ImmunoTherapy of Cancer 2051-1426 Biomed Central Ltd
    Journal for ImmunoTherapy of Cancer 2051-1426 Biomed Central Ltd
    Journal for ImmunoTherapy of Cancer 2051-1426 Biomed Central Ltd
    Journal for ImmunoTherapy of Cancer 2051-1426 Biomed Central Ltd
    Journal for Immunotherapy of Cancer 2051-1426 Bmc
    Journal for ImmunoTherapy of Cancer 20511426 Author(s) (or Their Employer(s)) 2024
    Journal for ImmunoTherapy of Cancer 2017 Nov 8-12 Biomed Central Ltd
    Journal for ImmunoTherapy of Cancer 2051-1426 Biomed Central Ltd
    Journal for ImmunoTherapy of Cancer 20511426 Bmj
    Journal for ImmunoTherapy of Cancer 2051-1426 Biomed Central Ltd
    Journal for ImmunoTherapy of Cancer 20511426 Author(s) (or Their Employer(s))
    Unknown (2051-1426) 2051-1426 Biomed Central Ltd